Cord Blood Expansion on Mesenchymal Stem Cells

Phase 1 Completed 98 enrolled M.D. Anderson Cancer Center National Cancer Institute (NCI) · collab National Institutes of Health (NIH) · collab ViaCell · collab

NaSingle-groupOpen-labelTreatment

Summary

The goal of this clinical research study is to learn if combining cord blood units will be safe and result in the cells "taking" faster in recipients. The cord blood units will have their cell number increased in the lab using cells from a family member or they will be collected from an unrelated healthy donor.

Timeline

Start: 2007-07-03
Primary completion: 2016-10
Completion: 2016-10

Publications

de Lima M, McNiece I, Robinson SN, Munsell M, Eapen M, Horowitz M, Alousi A, Saliba R, McMannis JD, Kaur I, Kebriaei P, Parmar S, Popat U, Hosing C, Champlin R, Bollard C, Molldrem JJ, Jones RB, Nieto Y, Andersson BS, Shah N, Oran B, Cooper LJ, Worth L, Qazilbash MH, Korbling M, Rondon G, Ciurea S, Bosque D, Maewal I, Simmons PJ, Shpall EJ. Cord-blood engraftment with ex vivo mesenchymal-cell coculture. N Engl J Med. 2012 Dec 13;367(24):2305-15. doi: 10.1056/NEJMoa1207285.

Drugs

Evaluation	Drug	Modality	Dose	Route
Background	Busulfan	Small molecule	32 mg/m2	Intravenous
Background	Clofarabine	Other / unclassified	30 mg/m2	Intravenous
Background	Cyclophosphamide	Other / unclassified	50 mg/kg	Intravenous
Background	Fludarabine	Small molecule	10 mg/m2	Intravenous
Background	Fludarabine	Small molecule	40 mg/m2	Intravenous
Background	G-CSF	Unknown	5 ug/kg	Subcutaneous
Background	Melphalan	Small molecule	140 mg/m2	Intravenous
Background	Mycophenolate Mofetil	Small molecule	1 g	Intravenous
Background	Rituximab	Monoclonal antibody	375 mg/m2	Intravenous
Background	Tacrolimus	Small molecule	0.03 mg/kg	Intravenous

Cord Blood Expansion on Mesenchymal Stem Cells

Summary

Timeline

Publications

Drugs

Indications